

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Confirmation No. 6580

NORDSTEDT et al.

Atty. Ref.: 117-580

Appln. No. 10/579,445

T.C. / Art Unit: Not Known

Filed: May 15, 2006

Examiner: Not Known

FOR: ANTIBODIES BINDING TO A C-TERMINAL FRAGMENT OF APOLIPOPROTEIN  
E

\* \* \* \* \*

**INFORMATION DISCLOSURE STATEMENT**

July 14, 2006

U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Further to the Information Disclosure Statement (IDS) filed May 15, 2006, Applicants submit a further Form PTO-1449 listing the enclosed documents.

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under 37 CFR § 1.97(f), to enable Applicants to comply fully. In particular, if any of the listed documents are missing or incomplete, please contact the undersigned who will provide another copy.


As provided by 37 CFR §§ 1.97(g) and (h), no inference should be made that this information and the listed references are prior art merely because they have been submitted for consideration. Furthermore, no representation is being made that a search has been conducted or that this statement encompasses all possible material information.

Consideration of the foregoing and enclosures, as well as the return of a copy of the Form PTO-1449 with the Examiner's initials per M.P.E.P. § 609, are earnestly solicited. The Examiner is invited to contact the undersigned if any further information is needed.


Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Gary R. Tanigawa  
Reg. No. 43,180

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100


**INFORMATION DISCLOSURE  
CITATION**

(Use several sheets if necessary)

APPLN. NO.

11/579,445

APPLICANT

NORDSTEDT et al.

FILING DATE

May 15, 2006

ATTY. DKT. NO.

117-580

GROUP

Not Known

**FOREIGN PATENT DOCUMENTS**

					TRANSLATION	
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
AR WO 94/09155	04/1994	WIPO				
BR WO 2004/011943	02/2004	WIPO				
CR EP 1434053 A1	06/2004	Europe				
DR						

**OTHER DOCUMENTS (including Author, Title, Pertinent pages, Date, etc.)**

ER	Aizawa et al. "Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brains: A possible role for apolipoprotein E in Alzheimer's disease" Brain Res. 768:208-214 (1997)
FR	Bi et al. "Rapid induction of intraneuronal neurofibrillary tangles in apolipoprotein E-deficient mice" Proc. Natl. Acad. Sci. USA 98:8832-8837 (2001)
GR	Bury et al. "1. Apolipoprotein quantification by ELISA: Technical aspects and clinical applications" Rev. Immuno. Technol. 1:1-25 (1998)
HR	Carlsson et al. "Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid" Clin. Chimica Acta 196:167-176 (1991)
IR	Castano et al. "Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L" J. Biol. Chem. 270:17610-17615 (1995)
JR	Demeester et al. "Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin: Cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease" J. Lipid Res. 41:963-974 (2000)
KR	Golabek et al. "Sodium dodecyl sulfate-resistant complexes of Alzheimer's amyloid $\beta$ -peptide with the N-terminal, receptor binding domain of apolipoprotein E" Biophys. J. 79:1008-1015 (2000)
LR	Harris et al. "Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice" Proc. Natl. Acad. Sci. USA 100:10966-10971 (2003)
MR	Huang et al. "Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons" Proc. Natl. Acad. Sci. USA 98:8838-8843 (2001)
NR	Klezovitch et al. "Structural determinants in the C-terminal domain of apolipoprotein E mediating binding to the protein core of human aortic biglycan" J. Biol. Chem. 275:18913-18918 (2000)
OR	Labeur et al. "Immunological assays of apolipoproteins in plasma: Methods and instrumentation" Clin. Chem. 36:591-597 (1990)
PR	Lee et al. "Microbial cell-surface display" Trends Biotechnol. 21:45-52 (2003)
QR	Lynch et al. "Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response" J. Neuroimmunol. 114:107-113 (2001)
RR	Mahley et al. "Apolipoprotein E structure, function, and possible roles in Alzheimer's disease" Ann. N.Y. Acad. Sci. 777:139-145 (1996)
SR	Namba et al. "Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease" Brain Res. 541:163-166 (1991)
TR	Näslund et al. "Characterization of stable complexes involving apolipoprotein E and the amyloid $\beta$ peptide in Alzheimer's disease brain" Neuron 15:219-228 (1995)
UR	Nishida et al. "Apolipoproteins J and E co-localise with amyloid in gelatinous drop-like and lattice type I corneal dystrophies" Br. J. Ophthalmol. 83:1178-1182 (1999)
VR	Perugini et al. "Self-association of human apolipoprotein E3 and E4 in the presence and absence of phospholipid" J. Biol. Chem. 275:36758-36765 (2000)

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**INFORMATION DISCLOSURE  
CITATION**

APPLN. NO.

11/579,445

ATTY. DKT. NO.

117-580

APPLICANT

NORDSTEDT et al.

(Use several sheets if necessary)

FILING DATE

May 15, 2006

GROUP

Not Known

**OTHER DOCUMENTS (including Author, Title, Pertinent pages, Date, etc.)**

AR	Pillot et al. "β-Amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: Relevance to Alzheimer's disease" J. Neurochem. 72:230-237 (1999)
BR	Saunders et al. "The role of apolipoprotein E in Alzheimer's disease: Pharmacogenomic target selection" Biochim. Biophys. Acta 1502:85-94 (2000)
CR	Sparrow et al. "Apolipoprotein E: Phospholipid binding studies with synthetic peptides from the carboxyl terminus" Biochem. 31:1065-1068 (1992)
DR	Terai et al. "Apolipoprotein E deposition and astrogliosis are associated with maturation of β-amyloid plaques in βAPPswe transgenic mouse: Implications for the pathogenesis of Alzheimer's disease" Brain Res. 900:48-56 (2001)
ER	Weisgraber et al. "Human apolipoprotein E: The Alzheimer's disease connection" FASEB J. 10:1485-1494 (1996)
FR	Wisniewski et al. "Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid" Neurosci. Lett. 135:235-238 (1992)
GR	Wisniewski et al. "Is Alzheimer's disease an apolipoprotein E amyloidosis?" Lancet 345:956-958 (1995)
HR	Chemicon International "Goat anti-apolipoprotein E polyclonal antibody," Catalog No. AB947 (2001)
IR	Chemicon International "Mouse anti-apolipoprotein E monoclonal antibody," Catalog No. MAB1062 (2002)
JR	Biodesign International, Catalog No. H61529M (2002)
KR	
LR	
MR	
NR	
OR	
PR	
QR	
RR	
SR	
TR	
UR	
VR	
WR	
XR	
YR	
ZR	
AAR	
BBR	
CCR	
DDR	

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)